KOSDAQBiotech & Pharma439580

Bluemtec

₩1,690▼ 4.57%2026-11-18 close
Market Cap
₩57.2B
Turnover
₩200M
Volume
120K
Shares out.
33.9M
PER
7.9×
PBR
1.2×
EPS
₩230
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrow and Turn Positive, but the Earnings Base Is Still Thin

Bluemtec's quarterly operating profit turned positive in 2026, but its 2025 operating margin was still negative and net losses attributable to controlling shareholders have continued for four consecutive years, so the durability of its earnings is not yet proven.

  1. 1

    Q3 2026 revenue reached KRW 90.4 billion, up 73.4% year on year, and operating profit for the quarter was KRW 1.08 billion.

  2. 2

    Cumulative operating profit for January to September was KRW 523 million, turning positive from a loss a year earlier.

  3. 3

    The 2025 operating loss narrowed to KRW 1.97 billion from KRW 6.9 billion in 2024, but the operating margin remained negative at -1.1%.

  4. 4

    Net losses attributable to controlling shareholders ran for four consecutive years from 2022 to 2025, while the last four quarters (Q4 2025 to Q3 2026) total KRW 5.63 billion in such profit.

  5. 5

    On October 30, 2026, the buyer position under the share purchase agreement was transferred to KDBI Healthcare Value-Up, and closing is scheduled for November 27, 2026.

02

Business structure

Bluemtec is a pharmaceutical distribution company founded in 2015, operating Bluefarm Korea, a B2B pharmaceutical e-commerce platform for clinics. It also runs a pharmacy-facing service and Bluedoc, a job platform for medical professionals.

According to the company, the platform had more than 36,200 members at the end of 2025, and 25,328 of the 37,514 clinic-level medical institutions nationwide (67.5%) had joined. The product mix is widening toward GLP-1 drugs, osteoporosis treatments and vaccines.

In aesthetics, the company distributes Medytox botulinum toxin products online and signed a filler and skin booster distribution agreement with Bioplus, disclosed on April 29, 2026.

The company attributed 2025 revenue growth mainly to demand for obesity drugs such as Wegovy and Mounjaro and to higher purchase volumes per loyal customer under its membership benefits.

In vaccines, the switch in the national flu vaccine from quadrivalent to trivalent created a supply-demand mismatch that led to KRW 1.8 billion in vaccine disposal losses in 2025. The company is reducing its flu vaccine share and expanding AI inventory management and personalized drug recommendations.

Its logistics rely on about 100 vehicles equipped with cold-chain systems. The company cites its clinic customer base and purchasing data as the basis of its platform competitiveness.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩52.1B₩300M0.7%
2025Q4₩53.9B-₩500M−0.9%
2026Q1₩44B-₩700M−1.7%
2026Q2₩55B₩200M0.3%
2026Q3₩90.4B₩1.1B1.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩77.1B₩900M-₩14.3B1.2%−1216.5%3326.2%
2023₩113.9B₩1.3B-₩2.3B1.2%−5.2%103.1%
2024₩133.3B-₩6.9B-₩4.8B−5.2%−10.2%145.4%
2025₩185.9B-₩2B-₩4.5B−1.1%−10.1%145.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 77.1 billion in 2022 to KRW 113.9 billion in 2023, KRW 133.3 billion in 2024 and KRW 185.9 billion in 2025, a 39.5% increase in 2025. Operating profit was KRW 891 million in 2022 and KRW 1.34 billion in 2023, but turned to an operating loss of KRW 6.9 billion in 2024.

The 2025 operating loss narrowed to KRW 1.97 billion, and the operating margin was -1.1%. The company said selling and administrative expense growth was held to about 2.4% while revenue rose more than 39%. Excluding the KRW 1.8 billion vaccine disposal loss in 2025, the company says gross margin exceeded 11%.

Net losses attributable to controlling shareholders were KRW 14.3 billion in 2022, KRW 2.34 billion in 2023, KRW 4.8 billion in 2024 and KRW 4.51 billion in 2025. Operating cash flow moved from -KRW 12.2 billion in 2024 to KRW 5.01 billion in 2025.

Quarterly, operating profit of KRW 347 million in Q3 2025 was followed by an operating loss of KRW 488 million in Q4 2025 and KRW 743 million in Q1 2026, before turning to KRW 182 million in Q2 2026 and KRW 1.08 billion in Q3 2026. The Q3 2026 operating margin was about 1.2%, which is low relative to revenue growth.

The company attributed Q3 growth to seasonal vaccine demand and clinic demand for GLP-1 and osteoporosis drugs. Profit attributable to controlling shareholders was KRW 2.64 billion in Q1 2026, KRW 1.98 billion in Q2 and KRW 937 million in Q3, a two-quarter decline. Reports said the first-half net profit turned positive partly because of derivative valuation gains.

05

Industry analysis

The pharmaceutical distribution market that Bluemtec serves is growing steadily on aging demographics and a rising chronic disease burden, and online drug purchasing is increasing.

The company highlights its clinic membership base as a core strength, saying it has signed up two of every three clinic-level medical institutions in Korea.

Among its main products, GLP-1 obesity drugs carry thin distribution margins, but strong demand has led drug makers to limit supply, pushing small clinics that struggle to secure inventory onto the platform.

The company believes biosimilars have lowered price barriers and could spread biologic drug use from tertiary hospitals to clinic-level institutions. It also views the aesthetics market as growing faster than the general drug market.

The 2025 results showed how product cycles can move earnings: obesity drug demand lifted revenue, while the flu vaccine regulatory change worked against the company. Demand is also seasonal, with the second half benefiting from flu season.

The company says about 16% of its platform members also run cosmetic or plastic surgery practices, indicating in-platform demand for aesthetic products. Market-share comparisons with other platforms are limited in the sources available.

06

Outlook

The company has set 2026 as the first year of a shift to profitability, pursuing a smaller flu vaccine share, better demand forecasting models and portfolio expansion. CEO Kim Jun-seok said revenue and profit structure should improve in the second-half flu season.

First-half 2026 revenue was KRW 99.0 billion, up KRW 19.2 billion year on year, and the operating loss narrowed to KRW 600 million. In a June 2026 report, Hana Securities projected 2026 revenue above KRW 200 billion and operating profit reaching breakeven.

The company plans to start a private-label business in medical consumables such as syringes and some IV fluids within 2026. A personalized platform service is planned for full launch in January 2027. In aesthetics, it is widening its range to fillers, skin boosters and cosmeceuticals.

The company identifies bio-drugs, aesthetics and premium vaccines as core categories and aims to raise the share of higher-growth products to lift both growth and profitability. Whether the company turns profitable for the full year 2026 depends on the operating profit scale in Q4, after the flu season.

The forward figures above come from a securities firm's projection rather than official company guidance, and no official annual target was identified in the sources.

07

Valuation

PER
7.9×
PBR
1.2×
ROE
12.0%
EPS
₩230
BPS
₩1,472
Dividend per share
₩0

Based on the last four quarters of profit attributable to controlling shareholders, which total KRW 5.63 billion, the earnings base is small, so valuation multiples can move sharply on a single quarter's results. The price-to-book ratio sits above 1, meaning the shares trade above book value.

Total equity at the end of 2025 of KRW 44.8 billion is entirely attributable to controlling shareholders, and the debt ratio fell from 3,326.2% in 2022 to 145.2% in 2025, a direction of balance sheet improvement.

Because the company is moving from losses to profit, earnings-based multiples rest on a thin base and can be read in many ways. A direct comparison with larger listed companies in the same industry is difficult given differences in business structure and earnings scale.

Shareholder returns have taken the form of treasury share cancellation rather than cash dividends, and total shares outstanding fell to 33,378,006 after cancellation. The control stake sale agreement was disclosed at KRW 23.07 billion, but as a block transaction amount it is not directly comparable with market prices.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Clinic-level member base

Membership exceeded 36,200 at the end of 2025, and 67.5% of clinic-level medical institutions nationwide have joined. The company sees this base as a launch pad for expanding into bio-drugs and aesthetic products. About 16% of members also run cosmetic or plastic surgery practices. The company says the member base is the starting point for diversifying its product range.

Revenue growth and a turn to profit

Cumulative revenue for January to September 2026 reached KRW 189.4 billion, up 43.5% year on year. Cumulative operating profit moved from a loss in the prior-year period to a profit. Q3 revenue of KRW 90.4 billion rose 73.4% from a year earlier.

The operating margin improved from -1.1% in 2025 to about 1.2% in Q3 2026, showing the direction of profitability improvement.

Ownership change and outside interest

The control stake sale was driven by a fund whose general partner is KDB Investment, and a subsidiary of Korea Kolmar Holdings reportedly joined as a strategic investor. Industry sources reportedly view the deal as reflecting high expectations for Bluemtec's growth.

Two pharmaceutical and biotech companies reportedly expressed interest in acquiring the stake. Any change in management direction after closing remains to be confirmed.

09

Bear factors

Low profitability and a thin earnings base

The 2025 operating margin was -1.1%, and net losses attributable to controlling shareholders ran for four consecutive years from 2022. The Q3 2026 operating margin was about 1.2%, low relative to revenue growth.

Profit attributable to controlling shareholders has declined for two consecutive quarters since its Q1 2026 peak. Because derivative valuation gains reportedly contributed to first-half net profit, they should be separated from core operating earnings.

Product margins and seasonality

GLP-1 obesity drugs carry low distribution margins, so revenue growth may not translate directly into higher margins. In 2025, the flu vaccine regulatory change produced KRW 1.8 billion in disposal losses.

Revenue swings sharply by quarter with flu season and vaccine demand, and Q1 2026 revenue fell 18.4% from the prior quarter to KRW 44 billion.

Ownership structure and dilution risk

Reports say the company decided to issue KRW 36 billion of unsecured private convertible bonds to Sanun Investment, and analysts noted that full conversion could push the ownership stake into the 40% range. Concerns about dilution for remaining shareholders have also been raised after the controlling stake sale.

The company dismissed concerns about redemption pressure, citing the bondholders' profile. Conversion volumes and ownership changes should be confirmed through future disclosures.

10

Risk factors

Product concentration risk

Much of the growth depends on demand for GLP-1 obesity drugs, which carry low distribution margins and whose sales mix could shift with manufacturer supply limits or demand changes. The vaccine segment has already seen disposal losses after the 2025 flu vaccine regulatory change. Reducing exposure to specific products and policy changes is central to the company's portfolio expansion.

Ownership and dilution risk

The control stake sale is conditional, with closing scheduled for November 27, 2026. If the convertible bonds convert, existing shareholders' stakes could be diluted.

Treasury share cancellation reduced total shares outstanding, but the possibility of convertible bond conversion and new share issuance should be tracked separately. Whether management and strategy change after the sale is still an open variable.

Earnings volatility risk

Reports say first-half net profit was supported by derivative valuation gains. Such gains and losses can move net income regardless of operating activity. Quarterly operating profit also swings with flu season and vaccine demand.

Operating profit and profit attributable to controlling shareholders can move in different directions, so the two should be read separately.

11

What to watch next

  1. November 27, 2026

    Scheduled closing date for the control stake sale. It is the point at which closing and any subsequent changes in management and strategy should be confirmed.

  2. End of 2026

    Whether the private-label medical consumables business the company planned to start within 2026 actually launches, and its effect on revenue mix and margins.

  3. January 2027

    Planned full launch of the personalized platform service. Member repeat purchasing and changes in purchase size are the points to watch.

  4. Around February 2027

    Expected timing of 2026 full-year results. Prior-year results were disclosed on February 9, 2026, and the Q4 operating profit and whether the full year turns profitable are the key checks.

  5. March 31, 2027

    Deadline for filing the 2026 annual business report. It is the point to confirm full-year and quarterly results finalized in the periodic report and related ownership disclosures.

12

Overall view

Bluemtec's revenue grew from KRW 77.1 billion in 2022 to KRW 185.9 billion in 2025, and Q3 2026 revenue jumped to KRW 90.4 billion. The operating loss narrowed from KRW 6.9 billion in 2024 to KRW 1.97 billion in 2025, and cumulative operating profit for 2026 turned positive.

However, the 2025 operating margin was -1.1% and the Q3 2026 margin was only about 1.2%, so it is too early to say profitability has caught up with revenue growth.

Net losses attributable to controlling shareholders have run for four consecutive years, and first-half net profit was supported by derivative valuation gains. Positive factors include the clinic member base, product expansion into obesity drugs and aesthetics, and the progress of the control stake sale.

Negative factors include a low-margin structure, vaccine seasonality and regulatory risk, and possible dilution from convertible bonds. The next checkpoints are the closing of the stake sale on November 27, 2026, the scale of Q4 2026 operating profit, and the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. etoday.co.kr
  4. newsquest.co.kr
  5. betanews.net
  6. etoday.co.kr
  7. hellot.net
  8. supple.kr
  9. medifonews.com
  10. medipharmhealth.co.kr
  11. news.nate.com
  12. m.irgo.co.kr
  13. kormedi.com
  14. mt.co.kr
  15. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis